SA Best Peanut Butter Business Plan — Financial Plan
Five-year projections with full income statement, cash flow and balance sheet: revenue to R161.72m and EBITDA to R17.47m.
Financial Plan
Jump to section
- Overview & contents
- i. Important Notice and Basis of Preparation
- 1. Executive Summary
- 2. Aflatoxin: The Question That Defines the Business
- 3. Market, Products and Pricing
- 4. Regulation and Food Safety
- 5. SWOT and Competitive Position
- 6. Operations
- 7. Financial Plan
- 8. Break-Even and Debt Service
- 9. Investment Analysis
- 10. Sensitivity and Scenario Analysis
- 11. Risk Analysis
- 12. Implementation Roadmap
- 13. Key Performance Indicators
- 14. Key Assumptions
- 15. Conclusion and Recommendation
- A. Appendix A: Consolidated Financial Summary
- B. Appendix B: Volume, Kernel and Cost Schedules
- C. Appendix C: Funding, Debt and Working Capital Schedules
- D. Appendix D: Risk Register
- E. Appendix E: Glossary
- 7.1 Basis of preparation
- 7.2 Income statement
- 7.3 Fixed costs and capital
- 7.4 Working capital
- 7.5 Cash flow
- 7.6 Balance sheet
- 7.7 Funding
7.1 Basis of preparation
▪ All figures are in South African Rand and exclude VAT.
▪ Revenue is built from tonnes produced, product mix and price per kilogram. Volume ramps from 900 t to 2 150 t, reaching 7.8% of the national market.
▪ Kernels are costed at R27 900 a tonne, adjusted for a recipe ratio of 0.905 tonnes of kernel per tonne of product and a 3.8% intake rejection allowance, giving R26 247 a tonne of finished product.
▪ Selling prices escalate at 6.2% a year and kernel costs at 6.8% — the spread compresses gently, reflecting that groundnut prices have historically outpaced food inflation.
▪ The blended selling price nonetheless rises faster than 6.2% because own brand grows from 30% to 49% of volume. Trade spend on own brand is 8.5% of own-brand revenue.
▪ The second shift is added in Year 2, adding R2 700 000 of annual fixed cost and R3 400 000 of capital.
▪ Depreciation is straight-line over five to fifteen years. Corporate income tax is 27%, with assessed losses carried forward subject to the section 20 limitation.
▪ Working capital assumes 48 debtor days, 42 days of kernel stock, 24 days of finished goods and 46 days to pay suppliers.
7.2 Income statement
|
R |
Year 1 |
Year 2 |
Year 3 |
Year 4 |
Year 5 |
|---|---|---|---|---|---|
|
Tonnes |
900 |
1 380 |
1 720 |
1 990 |
2 150 |
|
Blended price per kg |
R56.16 |
R60.97 |
R65.63 |
R70.26 |
R75.22 |
|
Revenue |
50 543 182 |
84 139 322 |
112 889 099 |
139 826 923 |
161 719 552 |
|
Kernel cost |
(23 622 300) |
(38 684 160) |
(51 493 360) |
(63 628 260) |
(73 418 200) |
|
Packaging |
(5 836 500) |
(9 696 126) |
(12 973 675) |
(16 018 703) |
(18 468 017) |
|
Conversion |
(4 842 000) |
(7 855 015) |
(10 358 147) |
(12 679 215) |
(14 493 171) |
|
Trade spend |
(1 288 851) |
(2 717 700) |
(4 126 097) |
(5 467 233) |
(6 735 619) |
|
Outbound logistics and additives |
(2 790 000) |
(4 526 124) |
(5 968 449) |
(7 305 867) |
(8 351 083) |
|
Gross profit |
12 163 531 |
20 660 197 |
27 969 371 |
34 727 645 |
40 253 462 |
|
Gross margin |
24.1% |
24.6% |
24.8% |
24.8% |
24.9% |
|
Fixed cash costs |
(15 690 142) |
(19 401 600) |
(20 468 688) |
(21 594 466) |
(22 782 161) |
|
EBITDA |
(3 526 611) |
1 258 597 |
7 500 683 |
13 133 179 |
17 471 301 |
|
EBITDA margin |
-7.0% |
1.5% |
6.6% |
9.4% |
10.8% |
|
Pre-opening costs, non-recurring |
(6 720 000) |
— |
— |
— |
— |
|
Depreciation |
(4 411 667) |
(4 751 667) |
(4 751 667) |
(4 751 667) |
(4 751 667) |
|
Finance costs |
(4 682 200) |
(4 682 200) |
(4 209 751) |
(3 683 349) |
(3 096 831) |
|
Profit / (loss) before tax |
(19 340 478) |
(8 175 270) |
(1 460 735) |
4 698 163 |
9 622 803 |
|
Taxation |
— |
— |
— |
(253 701) |
(519 631) |
|
Profit / (loss) after tax |
(19 340 478) |
(8 175 270) |
(1 460 735) |
4 444 462 |
9 103 172 |
|
Cumulative profit / (deficit) |
(19 340 478) |
(27 515 748) |
(28 976 483) |
(24 532 021) |
(15 428 849) |
|
Kernel cost as % of revenue |
46.7% |
46.0% |
45.6% |
45.5% |
45.4% |
Losses of R19 340 478 in Year 1, R8 175 270 in Year 2 and R1 460 735 in Year 3 accumulate to R28 976 483 of assessed loss. Under the section 20 limitation the set-off in any year is capped at the higher of R1 million or 80 per cent of taxable income, so Year 4 profit before tax of R4 698 163 is sheltered to R3 758 530, leaving R939 633 taxable and a charge of R253 701. Year 5 carries a charge of R519 631. R17 519 710 of assessed loss remains available at the end of Year 5 — a real asset against Year 6 and Year 7 earnings that no line of this plan values.
7.3 Fixed costs and capital
|
Fixed cost |
Annual |
Note |
|---|---|---|
|
Salaries and wages, excluding direct production labour |
6 230 142 |
17 staff; direct labour sits in conversion cost |
|
Factory lease and municipal services |
2 460 000 |
|
|
Marketing and brand building |
1 680 000 |
Own-brand building; separate from trade spend |
|
Insurance including product recall cover |
1 240 000 |
Product recall and product liability cover |
|
Plant maintenance contract |
1 060 000 |
|
|
Food safety certification, audits and accreditation |
720 000 |
A condition of the pricing assumed, not an overhead |
|
Administration, security and sundry |
680 000 |
|
|
Vehicle running and logistics management |
580 000 |
|
|
Professional fees, audit and compliance |
580 000 |
|
|
Information systems and traceability |
460 000 |
Lot-level traceability from intake to pallet |
|
Total cash fixed costs, one shift |
15 690 142 |
Plus depreciation of R4 411 667 |
|
Second shift, from Year 2 |
R2 700 000 |
Additional annual fixed cost |
|
Capital expenditure |
Amount |
Life |
|---|---|---|
|
Roasting, blanching and cooling line |
7 100 000 |
12 years |
|
Filling, capping and labelling lines, jar and pail |
6 400 000 |
10 years |
|
Grinding, milling and homogenising plant |
5 600 000 |
12 years |
|
Factory building fit-out, floors and food-grade finishes |
5 400 000 |
15 years |
|
Optical sorting and foreign body detection |
4 900 000 |
10 years |
|
Aflatoxin laboratory and analytical equipment |
3 400 000 |
8 years |
|
Raw material intake, silos and conditioned storage |
3 300 000 |
15 years |
|
Steam, compressed air and electrical reticulation |
2 600 000 |
12 years |
|
Finished goods warehouse racking and handling |
1 900 000 |
12 years |
|
Traceability, ERP and quality management systems |
1 900 000 |
5 years |
|
Professional fees, commissioning and validation |
1 700 000 |
10 years |
|
Standby generation |
1 600 000 |
12 years |
|
Metal detection, X-ray and end-of-line inspection |
1 600 000 |
10 years |
|
Total capital expenditure |
47 400 000 |
|
|
Second shift capital, Year 2 |
3 400 000 |
10 years |
Optical sorting at R4 900 000 and the aflatoxin laboratory at R3 400 000 together are R8 300 000, or 17.5 per cent of the capital programme, and neither improves the product a consumer can taste. They exist to keep the plant out of Section 2.2, and they are the clearest illustration in this plan of the distinction between making peanut butter and making it safely.
7.4 Working capital
|
R |
Year 1 |
Year 2 |
Year 3 |
Year 4 |
Year 5 |
|---|---|---|---|---|---|
|
Trade receivables at 48 days |
6 646 775 |
11 064 897 |
14 845 690 |
18 388 198 |
21 267 229 |
|
Kernel stock at 42 days |
2 718 182 |
4 451 328 |
5 925 263 |
7 321 608 |
8 448 122 |
|
Finished goods at 24 days |
2 523 593 |
4 173 970 |
5 583 763 |
6 910 637 |
7 986 811 |
|
Less trade payables at 46 days |
(4 064 232) |
(6 667 657) |
(8 876 801) |
(10 958 439) |
(12 632 646) |
|
Working capital employed |
7 824 318 |
13 022 538 |
17 477 915 |
21 662 004 |
25 069 516 |
|
As a share of revenue |
15.5% |
15.5% |
15.5% |
15.5% |
15.5% |
|
Facility drawn at year end |
3 633 129 |
19 791 981 |
25 565 904 |
25 689 744 |
24 964 815 |
|
Headroom on the R26 000 000 facility |
22 366 871 |
6 208 019 |
434 096 |
310 256 |
1 035 185 |
7.5 Cash flow
|
R |
Year 1 |
Year 2 |
Year 3 |
Year 4 |
Year 5 |
|---|---|---|---|---|---|
|
Profit / (loss) after tax |
(19 340 478) |
(8 175 270) |
(1 460 735) |
4 444 462 |
9 103 172 |
|
Add back: depreciation |
4 411 667 |
4 751 667 |
4 751 667 |
4 751 667 |
4 751 667 |
|
Add back: pre-opening costs funded at day zero |
6 720 000 |
— |
— |
— |
— |
|
Movement in working capital |
(7 824 318) |
(5 198 220) |
(4 455 377) |
(4 184 089) |
(3 407 512) |
|
Cash generated from operations |
(16 033 129) |
(8 621 823) |
(1 164 445) |
5 012 040 |
10 447 327 |
|
Capital deployed |
— (funded at close) |
(3 400 000) |
— |
— |
— |
|
Debt capital repaid |
— (moratorium) |
(4 137 029) |
(4 609 478) |
(5 135 880) |
(5 722 398) |
|
Net movement before facility |
(16 033 129) |
(16 158 852) |
(5 773 923) |
(123 840) |
4 724 929 |
|
Facility drawn / (repaid) |
3 633 129 |
16 158 852 |
5 773 923 |
123 840 |
(724 929) |
|
Closing cash |
7 600 000 |
7 600 000 |
7 600 000 |
7 600 000 |
11 600 000 |
Opening cash after the capital programme and the non-working-capital soft costs is R16 400 000. Operations consume R16 033 129 in Year 1 and R8 621 823 in Year 2, turn positive at R5 012 040 in Year 4 and reach R10 447 327 by Year 5. The working capital facility is drawn progressively to R25 689 744 by Year 4 and begins to repay in Year 5. Cash is held at R7 600 000 throughout the ramp by drawing against the facility, which is what the facility is for.
7.6 Balance sheet
|
R, at year end |
Year 1 |
Year 2 |
Year 3 |
Year 4 |
Year 5 |
|---|---|---|---|---|---|
|
Plant, laboratory and building, net of depreciation |
42 988 333 |
41 636 666 |
36 884 999 |
32 133 332 |
27 381 665 |
|
Kernel stock |
2 718 182 |
4 451 328 |
5 925 263 |
7 321 608 |
8 448 122 |
|
Finished goods |
2 523 593 |
4 173 970 |
5 583 763 |
6 910 637 |
7 986 811 |
|
Trade receivables |
6 646 775 |
11 064 897 |
14 845 690 |
18 388 198 |
21 267 229 |
|
Cash |
7 600 000 |
7 600 000 |
7 600 000 |
7 600 000 |
11 600 000 |
|
Total assets |
62 476 883 |
68 926 861 |
70 839 715 |
72 353 775 |
76 683 827 |
|
Share capital |
33 120 000 |
33 120 000 |
33 120 000 |
33 120 000 |
33 120 000 |
|
Retained earnings / (accumulated loss) |
(19 340 478) |
(27 515 748) |
(28 976 483) |
(24 532 021) |
(15 428 849) |
|
Total equity |
13 779 522 |
5 604 252 |
4 143 517 |
8 587 979 |
17 691 151 |
|
Term facilities — non-current |
36 862 971 |
32 253 493 |
27 117 613 |
21 395 215 |
15 043 353 |
|
Term facilities — current |
4 137 029 |
4 609 478 |
5 135 880 |
5 722 398 |
6 351 862 |
|
Working capital facility drawn |
3 633 129 |
19 791 981 |
25 565 904 |
25 689 744 |
24 964 815 |
|
Trade payables |
4 064 232 |
6 667 657 |
8 876 801 |
10 958 439 |
12 632 646 |
|
Total liabilities |
48 697 361 |
63 322 609 |
66 696 198 |
63 765 796 |
58 992 676 |
|
Total equity and liabilities |
62 476 883 |
68 926 861 |
70 839 715 |
72 353 775 |
76 683 827 |
Net book value of the plant, laboratory and building declines from R42 988 333 to R27 381 665 as depreciation runs against a capital programme that completes in Year 2. Total equity falls from R33 120 000 at inception to a low of R4 143 517 at the end of Year 3 and recovers to R17 691 151 by Year 5. Gearing peaks at 94.1 per cent at the end of Year 3 — the point at which the accumulated deficit is deepest and the working capital facility most drawn — and falls to 71.8 per cent by Year 5.
7.7 Funding
|
Source |
Amount |
Share |
Terms |
|---|---|---|---|
|
Promoter and investor equity |
33 120 000 |
44.7% |
Sized to carry three loss-making years without a further call |
|
DFI facility |
16 000 000 |
21.6% |
Eight years at 11.42% with a one-year capital moratorium |
|
Senior debt |
25 000 000 |
33.7% |
Eight years at 11.42% with a one-year capital moratorium |
|
Total funding requirement |
74 120 000 |
100.0% |
|
|
Working capital facility |
26 000 000 |
Committed at drawdown; drawn to R25 689 744 at its peak |
|
Use of funds |
Amount |
Share |
|---|---|---|
|
Capital expenditure |
47 400 000 |
64.0% |
|
Working capital: kernel stock and finished goods |
16 400 000 |
22.1% |
|
Retail listing fees and launch trade investment |
3 600 000 |
4.9% |
|
Pre-operational salaries, recruitment and training |
2 100 000 |
2.8% |
|
Brand development, packaging design and launch |
1 900 000 |
2.6% |
|
Commissioning, trial production and shelf-life testing |
1 480 000 |
2.0% |
|
Certification, accreditation and regulatory approvals |
1 240 000 |
1.7% |
|
Total |
74 120 000 |
100.0% |